AI assistant
HIKMA Pharmaceuticals PLC — Director's Dealing 2019
Sep 6, 2019
4841_dirs_2019-09-06_0cd00bcd-4ed3-4405-9719-a2f0a107d3f4.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 5610L
Hikma Pharmaceuticals Plc
06 September 2019
Notification and public disclosure of transactions by person discharging managerial responsibilities
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Said Darwazah |
| 2 | Reason for the notification | |
| a) | Position/status | Executive Chairman |
| b) | Initial notification /Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Hikma Pharmaceuticals PLC |
| b) | LEI | 549300BNS685UXH4JI75 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 |
| b) | Nature of the transaction | Disposal of 150,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC by Banque Lombard Odier & Cie SA |
| c) | Price(s) and volume(s) | Price(s): £20.56 Volume(s): 49,826 Price(s): £19.85 Volume(s): 25,000 Price(s): £19.82 Volume(s): 25,000 Price(s): £19.84 Volume(s): 25,000 Price(s): £19.82 Volume(s): 25,174 |
| d) | Aggregated information | Aggregated volume: 150,000 Price: £20.07 Total: £3,011,121 |
| e) | Date of the transaction | 4 and 6 September 2019 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
Peter Speirs, Company Secretary, Responsible for releasing this announcement
6 September 2019
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
DSHBSGDCXDGBGCL